MARKET
IPO

CSTX

Cirius Therapeutics
CSTX
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
Pharmaceuticals
2019-01-11
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 82.31M
Listed
No Data
About CSTX
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and metabolic diseases. The Company’s lead product candidate, MSDC-0602K, is a novel, once-daily, oral small molecule focused on treating nonalcoholic steatohepatitis, or NASH, with fibrosis. MSDC-0602K selectively modulates the mitochondrial pyruvate carrier, or MPC, which mediates at the cellular level the effects of overnutrition, a cause of NASH and other metabolic disorders.

Webull offers Cirius Therapeutics stock information, including NASDAQ: CSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSTX stock methods without spending real money on the virtual paper trading platform.